The epoxyeicosatrienoic acids (EETs) are products of cytochrome P450 (CYP) epoxygenases that have vasodilatory and anti-inflammatory properties. Here we report that EETs have additional fibrinolytic properties. In vascular endothelial cells, physiological concentrations of EETs, particularly 11,12-EET, or overexpression of the endothelial epoxygenase, CYP2J2, increased tissue plasminogen activator (t-PA) expression by 2.5-fold without affecting plasminogen activator inhibitor (PAI)-1 expression. This increase in t-PA expression correlated with a 4-fold induction in t-PA gene transcription and a 3-fold increase in t-PA fibrinolytic activity, and was blocked by the CYP inhibitor, SKF525A, but not by the K Ca2+ channel blocker, charybdotoxin, indicating a mechanism which does not involve endothelial cell hyperpolarization. The t-PA promoter is cyclic AMP (cAMP)-responsive and induction of t-PA gene transcription by EETs correlated with increases in intracellular cAMP levels, and functionally, with cAMP-driven promoter activity. To determine whether increases in intracellular cAMP levels were due to modulation of guanine nucleotide-binding proteins, we assessed the effects of EETs on Gα s and Gα i2 . Treatment with EETs increased Gα s , but not Gα i2 , GTP-binding activity by 3.5-fold. These findings indicate that EETs possess fibrinolytic properties through the induction of t-PA and suggest that endothelial CYP2J2 may play an important role in regulating vascular hemostasis.
INTRODUCTION
The epoxyeicosatrienoic acids (EETs) are important vasoactive products of cytochrome P450 epoxygenases (1) (2) (3) . The EETs have properties similar to that of endothelium-derived hyperpolarizing factor (EDHF) because they hyperpolarize and relax vascular smooth muscle cells by activating calcium-sensitive potassium (K Ca2+ ) channels (4, 5) . Recently, two CYP epoxygenases, CYP2C8 and CYP2J2, have been identified in vascular endothelial cells (1, 6) .
Although both enzymes produce EETs, the regulation of CYP2C8 and CYP2J2 appears to be somewhat different and their products may exert additional non-vasodilatory effects. For example, Fisslthaler and co-workers have shown that treatment of porcine coronary artery endothelial cells in vitro with β-naphthoflavone induces CYP2C8 expression, increases 11,12-EET biosynthesis, and enhances EDHF-mediated coronary artery relaxation (1) . However, β-Naphthoflavone does not induce the CYP2J subfamily enzymes (7) . Furthermore, we have recently reported that EETs possess anti-inflammatory properties through the inhibition of the pro-inflammatory transcriptional factor, NF-κB (6) . In contrast to their vasodilatory effects, the anti-inflammatory effects of EETs do not involve endothelial cell hyperpolarization. These studies, therefore, indicate that EETs have multiple homeostatic effects on the vascular wall in addition to their vasodilatory effects.
An interesting observation is that endogenous vasodilators such as nitric oxide (NO)
frequently possess anti-inflammatory (8) , anti-thrombotic (9) , and anti-proliferative properties staining with anti-Factor VIII antibodies (Vector Labs, Inc., Burlingame, CA). All passages were performed with a disposable cell scraper (Costar), and only endothelial cells of less than six passages were used. Confluent endothelial cells (~2 x 10 6 for human and ~5 x 10 6 for bovine)
were treated with various concentrations of EETs for the indicated time intervals.
Measurements of EETs
The method used to quantify endogenous EETs present in bovine aortic endothelial cells were similar to those used to quantify EETs in tissue preparations (7, 16, 17) . Briefly, 8 x 10 6 endothelial cells were frozen in liquid nitrogen, homogenized in 15 ml phosphate-buffered saline containing triphenylphosphine (10 mg), and the homogenate was extracted under acidic conditions with two volumes of chloroform/methanol (2:1) and twice more with an equal volume of chloroform. The combined organic phases were evaporated in tubes containing mixtures of [1- 14 C]8,9-, 11,12-and 14,15-EET internal standards (57 µCi/µmole, 30 ng each) which were synthesized from [1-14 C]arachidonic acid by nonselective epoxidation (18) . Saponification to recover phospholipid-bound EETs was followed by silica column purification. The eluent, containing a mixture of radiolabeled internal standards and total endogenous EETs was resolved into individual regioisomers by HPLC as described (7, 16, 17) . For analysis, aliquots of individual EET-PFB esters were dissolved in dodecane and analyzed by gas chromatography/mass spectrometry (GC/MS) as described (7, 16, 17) . Quantifications were made by selected ion monitoring at m/z 319 (loss of PFB from endogenous EET-PFB) and m/z 321 (loss of PFB from
EET-PFB ratios were calculated from the integrated values of the corresponding ion current intensities.
Measurement of t-PA Expression and Activity
The amounts of t-PA and PAI-I antigens expressed by endothelial cells were determined using the Imulyse™ reagent kits from Biopool (Umea, Sweden) according to the manufacturer's instruction. The t-PA activity in endothelial cell supernatants was determined by a chromogenic assay (Spectrolyse/Fibrin, Biopool). The t-PA in the supernatant from conditioned cells was bound using a specific t-PA monoclonal antibody (SP-322). Preliminary studies indicate that the SP-322 antibody completely bound all of the t-PA without affecting subsequent t-PA activity.
The t-PA substrate consisting of plasminogen, plasmin-sensitive chromogenic substrate, and cofactors for t-PA activity (HEPES buffer, pH 8.5) were added to the bound t-PA and absorption was read at 405 nm. The standard curve was constructed using human single-chain t-PA, which has been calibrated against an international standard for t-PA (Lot 66570, NIBSC, Hartfordshire, UK).
Northern Blotting
Equal amounts of total RNA (20 µg) were separated by 1.2% formaldehyde-agarose gel electrophoresis, transferred overnight onto Hybond nylon membranes (Amersham Corp., Arlington Heights, IL) by capillary action, and baked for 2 h at 80 °C before prehybridization.
Radiolabeling of full-length human t-PA or PAI-1 cDNA was performed using random hexamer 
RESULTS

Cell Culture
There were no observable effects of synthetic EETs or 11,12-DHET, the hydration metabolite of 11,12-EET, on cell number, morphology, or immunofluorescent staining for Factor VIII-related antigens. Cellular confluence and viability as determined by trypan blue exclusion was maintained for all treatment conditions described.
Endothelial Arachidonic Acid Metabolism and Detection of Endogenous EETs
We have previously shown that bovine endothelial cells metabolize radiolabeled arachidonic acid to epoxygenase products (EETs and DHETs) and that endothelial EET biosynthesis is augmented by transfection with an expression vector containing the CYP2J2 cDNA (6) . Using a combination of HPLC and GC/MS techniques, we detected EETs as endogenous constituents of cultured bovine aortic endothelial cells (Table 1) . Endothelial cells contained 7.98 ± 0.90 ng of EET per 10 7 cells. The 8,9-, 11,12-, and 14,15-EET regioisomers were each present in roughly equal amounts (40%, 28%, and 32% of total EETs, respectively). The labile 5,6-EET suffers extensive decomposition during the extraction and purification process used and therefore cannot be quantified. Transfection of endothelial cells with the pcDNA3.1 vector containing the CYP2J2 cDNA resulted in a significant 30% increase in total EETs that was due largely due to increases in 11,12-and 8,9-EET ( Table 1) . Treatment of CYP2J2 transfected cells with SKF525A (100 µM) significantly reduced total EETs to control levels. The documentation of EETs in endothelial cells provides direct evidence to support the epoxidation of endogenous arachidonic acid pools by endothelial cytochrome P450s.
Effects of EETs on t-PA Expression and Activity
In a concentration-dependent manner, treatment of endothelial cells with physiologically relevant concentrations of 5,6-, 8,9-, 11,12-, 14,15-EET, or 11,12-DHET (1-1000 nM, 24 h) increased t-PA protein levels (Fig. 1A) . Maximal increase was achieved with 11,12-EET at 100
nM. Interestingly, 14,15-and 8,9-EET induced significantly less t-PA expression than 11,12-EET indicating differential bioactivity of specific EET regioisomers. The increase in t-PA protein levels by 11,12-EET correlated with increases in t-PA steady-state mRNA levels (Fig.   1B ). Concentrations of 10 and 100 nM of 11,12-EET increased t-PA mRNA levels by 40 ± 5 and 95 ± 6%, respectively (p < 0.05 for both, n = 3). Consistent with effects on t-PA protein levels, a higher concentration of 11,12-EET (i.e. 1000 nM) also did not produce any further increase in t-PA mRNA levels. Interestingly, the increase in t-PA mRNA expression was not due to the membrane hyperpolarizating effects of EETs since the selective K Ca2+ blocker, charybdotoxin (100 nM), was unable to inhibit the increase in t-PA expression by 11,12-EET.
The increase in t-PA expression by 11,12-EET correlated with a 2.8-fold increase in t-PA fibrinolytic activity ( Fig. 2A) . Maximal t-PA fibrinolytic activity was observed at 100 nM of 11,12-EET. However, 10 nM of 11,12-EET which produced a smaller increase in t-PA expression compared to that of 100 nM, did not produce significant increases in t-PA fibrinolytic activity. This may be due to endogenous levels of PAI-1, which is known to bind and inhibit t-PA (13). However, in contrast to t-PA, EETs have no effect on PAI-I protein levels (Fig. 2B ). These findings suggest that treatment with EETs would favor fibrinolysis by increasing the ratio of t-PA to PAI-1.
In a time-dependent manner, 11,12-EET (100 nM) increased t-PA protein levels with maximal increase occurring after 24 h of exposure (Fig. 3A) . This increase in t-PA expression was attenuated by co-treatment with the translational inhibitor, cycloheximide (CHX, 5
µmol/L), indicating that 11,12-EET does not promote the release of already synthesized t-PA but that de novo protein synthesis was required. Since t-PA expression is known to be induced by agents or conditions which increase cAMP-dependent pathways (21-23), we investigated whether the induction of t-PA expression by EETs was mediated by the cAMP-dependent kinase such as protein kinase A (PKA). Co-treatment with the PKA inhibitor, H-89 (30 µM), almost completely inhibited EET-induced t-PA expression (Fig. 3B) . Again, the selective K Ca2+ blocker, charybdotoxin (100 nM), was unable to inhibit the increase in t-PA expression by 11,12-EET suggesting a non-hyperolarizing effect of EETs on t-PA expression.
Effects of EETs and CYP2J2 on t-PA Gene Transcription
Using a -3.1 kb human t-PA promoter linked to a luciferase reporter (pt-PA.Luc), we found that 11,12-EET, and to a lesser extent, 11,12-DHET, increased t-PA promoter activity in a concentration-dependent manner (Fig.4A) . A maximal 4. PA promoter activity, which was almost completely blocked by the nonspecific cytochrome P450 epoxygenase inhibitor, SKF525A (Fig. 4B) . The K Ca2+ blocker, charybdotoxin, however, had no effect on EET-induced t-PA promoter activity. These findings suggest that CYP2J2-derived eicosanoids increase t-PA gene transcription. 
Effects of EETs and CYP2J2 on cAMP-dependent Gene Transcription
The induction of t-PA gene transcription is regulated, in part, by increases in intracellular cAMP (21) (22) (23) . We found that EETs, particularly 11,12-EET, increased intracellular cAMP levels in a concentration-dependent manner (Fig. 5A) . Treatment with 11,12-EET (100 nM) produced a 3-fold increase in intracellular cAMP levels (3. In support of the role of cAMP in CRE-mediated gene transcription, we found that the increase in pCRE-Luc activity by 11,12-EET (100 nM) was inhibited in a time-dependent manner by inhibition of the cAMP-dependent kinase, PKA (Fig. 6A) . Treatment with the PKA inhibitor, H-89, decreased 11,12-EET-induced CRE promoter activity by 70% after 24 h. To determine whether endogenous EETs produced by CYP2J2 can increase CRE promoter activity, we co-transfected endothelial cells with pcDNA3.1/CYP2J2. Compared to transfection with the empty pcDNA3.1 vector, overexpression of pcDNA3.1/CYP2J2 increased CRE promoter activity by 7.3-fold after 12 h (Fig. 6B ). This effect was almost completely blocked in the presence of the cytochrome P450 inhibitor, SKF525A. These findings suggest that CYP2J2-derived eicosanoids can functionally increase CRE promoter activity.
Effects of EETs on G Proteins
To determine the whether the increase in cAMP is due to the effects of EETs on G proteins, we measured Gα i2 and Gα s GTP-binding activities in membranes from endothelial cells treated with EETs. Treatment with 11,12-EET (10-1000 nM, 5 min) caused a progressive increase in Gα s GTP-binding activity with a maximal 3-fold increase (6.1 ± 2.1 to 18.5 ± 1.2 fmol/min/mg, p<0.01, n=3) occurring at concentration of 100 nM (Fig. 7A) 7B ). These findings suggest that the effects of EETs on cAMP levels, CRE promoter activity, and t-PA expression/activity are likely mediated by their stimulatory effects on Gα s .
DISCUSSION
We have shown that EETs, particularly 11,12-EET, increase endothelial t-PA expression and activity by a transcriptional mechanism involving activation of Gα s . The activation of Gα s leads to the stimulation of adenylyl cyclase, increase in intracellular cAMP, and induction of cAMP-dependent promoter activity. The effect of EETs on Gα s activity is rather specific since EETs did not affect basal or UK14304-stimulated Gα i2 activity. Because Gα i2 is specifically coupled to UK14304-stimulated α 2 -adrenergic receptor in vascular endothelial cells (24), these results suggest that EETs selectively modulate Gα s activity. The net effect of EETs on G proteins, therefore, is to favor receptor-mediated activation of adenylyl cyclase. Indeed, inhibition of cAMP-dependent PKA inhibits EET-induced t-PA expression and CRE promoter activity. These findings are in agreement with previous studies which showed that arteriolar vasodilation by sulfonimide analogs of 11,12-EET analogs is associated with elevation in intracellular cAMP levels and increase in PKA activity (25) .
The precise mechanism by which EETs alter membrane signal transduction and increase t-PA expression is not known. Previous studies have shown that 11,12-EET stimulates the ADPribosylation of a number of intracellular proteins in vascular smooth muscle including Gα s (26, 27) . Indeed, the binding of 14,15-EET to its putative receptor in U937 cells leads to the increase in cAMP levels and PKA activity and subsequently, to a decrease in its receptor binding (28) . Thus, it is possible that EET-induced ADP-ribosylation of Gα s results in the activation of Gα s similar to that of cholera toxin. Although we cannot exclude the additional possibility that EETs may induce similar changes in other G-proteins, these effects of EETs, however, are unlikely given that Gα i2 activity was not affected. It is also possible that EETs may induce changes in the level of Gα s and Gα i2 . However, under the conditions of our study, the observed changes in Gα s activity and cAMP levels occurred within 5 min; which is somewhat rapid for a transcriptional effect on G proteins. Nevertheless, the downstream effect of cAMP is dependent upon de novo protein synthesis since the protein synthesis inhibitor, cycloheximide, was able to attenuate EET-induced t-PA expression.
The regulation of gene transcription by cAMP is mediated by trans-acting factors, which bind to cAMP-response element (CRE) (5'-ATGACGTCAT-3') of target genes (29) . Although the consensus sequence for CRE is not present in the t-PA promoter, a functional CRE-like element has been identified which acts synergistically with a putative AP-2 binding site to induced t-PA gene transcription by phorbol 12-myristate 13-acetate (22) . Indeed, previous studies have shown that cholera toxin and dibutyryl-cAMP can directly induce t-PA gene transcription in rat hepatocytes (30, 31) . Furthermore, we have previously shown that low concentrations of alcohol enhance isoproterenol-induced t-PA gene transcription via increase in cAMP levels and induction of CRE promoter activity in vascular endothelial cells (32) . These studies, therefore, suggest that the activation of CRE and CRE-binding protein(s) (CREBP) may play an important role in mediating the induction of t-PA by EETs.
The vasodilatory effect of EETs, which resemble EDHF, is mediated by activation of K Ca2+ channels and subsequent hyperpolarization of vascular smooth muscle membranes (4,5). The anti-inflammatory effect of EETs involve inhibition of cellular adhesion molecule expression via inhibition of NF-κB activation (6). The anti-proliferative effect of EETs has not been reported and we do not find that 11,12-EET inhibits platelet-derived growth factor (PDGF)-induced smooth muscle cell or fibroblast proliferation (unpublished data). Our study showed that EETs possess anti-fibrinolytic properties through the induction of t-PA expression. By linking EETs to the fibrinolytic pathway, another important non-vasodilatory action of EETs is suggested, and the homeostatic role of EETs in the vascular wall is broadened considerably because thrombosis is implicated in vascular occlusive disease and atherosclerosis (11, 12) . In this respect, EETs are similar to endothelium-derived nitric oxide (NO), which relaxes vascular smooth muscle (33), inhibits NF-κB (8), and prevents platelet aggregation (9) . The mechanism by which EETs exert these effects, however, are quite distinct from that of NO, which suggests that cAMP-and cGMP-dependent pathways may work in concert to regulate vascular hemastasis.
The finding that EET induces t-PA may have important clinical implications since the etiology of acute coronary syndromes is thought to be due to atherosclerotic plaque rupture with ensuing vascular thrombosis and occlusion (11, 12) . Our results, therefore, suggest that
EETs may lower the risks of cardiovascular disease by augmenting t-PA levels and enhancing the overall fibrinolytic activity in the vascular wall. However, in contrast to the fibrinolytic effect of EETs, other cytochrome P450-derived eicosanoids have been shown to have opposing effects. For example, 15-hydroxyeicosatrienoic acid (15-HETE), an arachidonic acid metabolite that is produced via oxidation and ketoreduction, has been shown to decrease t-PA expression (34) . The concentrations of EETs used in our study are within the physiological concentrations of EETs measured in the bloodstream of healthy humans and rats which is approximately 30 nM (16). However, it should be noted that EET levels in human and rat heart tissues are estimated to be 6-to 7-fold higher (35) and may be even higher during vascular injury and inflammation.
In summary, our findings suggest that EETs may play an important role in regulating the fibrinolytic balance in the vessel wall. The potency of EETs' anti-fibrinolytic effects suggest that the biological actions of these cytochrome P450-derived eicosanoids, like those of the prostaglandins and leukotrienes, may be mediated through specific cell-surface receptors. The identification and functional characterization of putative EET receptor(s) would greatly aid future research in this field. 
